If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
175
results.
Updated on
07/06/2025 [07:45:00]
Results 100 to 125 of 175
Absstract of: US2025134985A1
Provided herein, in some aspects, are methods for using the receptor-binidng domain (RBD) of the SARS-COV-2 S protein, including the the RBD-1, RBD-2, and/or RBD-3 regions, to identify therapeutics for the treatment of SARS-COV-2, developing a vaccine for the treatment or prevention of SARS-COV-2, and identifying a patient as being in need for a treatment for SARS-COV-2.
Absstract of: US2025134989A1
The present invention relates to a novel vaccine composition for coronavirus infection-19 comprising a polymer-based mRNA carrier. Specifically, the present invention provides a vaccine composition comprising an mRNA carrier using a novel polymer capable of delivering a negatively charged genetic material such as mRNA, and the vaccine composition has excellent effects of enhanced in vivo immune activity such as high antibody formation ability and increased interferon-gamma production.
Absstract of: US2025136668A1
The present disclosure relates to an antibody or antigen-binding fragment thereof that specifically binds to a spike protein of SARS-CoV-2. The present disclosure also relates to a pharmaceutical composition, a method for treating and/or preventing diseases and/or disorders caused by a coronavirus in a subject in need thereof, and a method for detecting a coronavirus in a sample.
Absstract of: US2025134910A1
The present invention relates to a composition for treating coronavirus infection-19 (COVID-19), comprising taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof and an antiviral agent as active ingredients, it was confirmed that clinical symptoms were cured in patients with COVID-19 pneumonia who were administered a combination of a pharmaceutically acceptable salt of taurodeoxycholic acid as an inflammasome inhibitor and an antiviral agent, and thus this combination of taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof as an inflammasome inhibitor and an antiviral agent, holds promise as active ingredients in compositions for the prevention or treatment of lower respiratory tract infectious diseases, including COVID-19.
Absstract of: US2025134924A1
Compositions and methods for protecting against a wide spectrum of viral and bacterial infections, including Covid-19, and for treating established infection and infectious inflammation are described. The composition includes a novel combination of vitamins, minerals, nutraceuticals, and phytochemicals, which may be compounded as a pill, tablet, powder, capsule or liquid to be taken orally or via other administration routs one or more times per day, to serve as immune boosters, antibacterial agents, and antiviral agents along with providing anti-inflammatory effects in humans and animals.
Absstract of: WO2025086933A1
The present invention provides a new tea fraction, which is made from the non-ethanol extract, and does not contain caffeine, epigallocatechin gallate (EGCG), gallic acid and catechin that are usually found in conventional tea extracts. The tea fraction has an efficacy in treating a lung fibrosis, particularly idiopathic pulmonary fibrosis (IPF), Covid-19 and long Covid.
Absstract of: WO2025089473A1
The present invention provides: a peptide set for quantifying and analyzing antigen proteins of individual subtypes from a specimen containing antigen proteins of a plurality of SARS-CoV-2 subtypes; and a method for simultaneously and quantitatively analyzing antigen proteins of SARS-CoV-2 subtypes according to types thereof, using same. The peptide set comprises one or more peptides specific to individual SARS-CoV-2 subtypes, selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 3, and a peptide common to SARS-CoV-2 subtypes, selected from SEQ ID NO: 4 or SEQ ID NO: 5.
Absstract of: WO2025090048A1
The invention relates to an optimer-based electrochemical biosensor for use in the determination of SARS-CoV-2 S1 protein and Moxifloxacin as well as the method for its operation. The invention also includes an application of said method for the diagnosis of disease and the determination of drugs. In this context, SARS-CoV-2 S1 protein and Moxifloxacin were selected as target analytes and electrochemical analyses of these target analytes were performed using optimer-based procedure and electrochemical impedance spectroscopy technique.
Absstract of: WO2025090967A1
Provided herein are compositions and methods for treating musculoskeletal disorder such as arthritis, rheumatoid arthritis, osteoporosis, wound healing, corneal epithelial dystrophies and injuries, and cytokine storm with a molecule of formula: and one or more pharmaceutical acceptable excipients or salts; and methods for preventing and/or treating musculoskeletal disorder such as arthritis, rheumatoid arthritis, osteoporosis, wound healing, corneal epithelial dystrophies and injuries, and cytokine storm triggered by a coronavirus 2 (SARS-CoV-2) infection or fibrosis in a subject.
Absstract of: WO2025090605A1
The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
Absstract of: WO2025088482A1
The present invention relates to a composition, preferably a nutraceutical composition, for use in a method of treatment of subjects over 50 suffering from chronic fatigue, particularly due to: arthritis/chronic arthritis; heart disease; post-operative convalescence; depression; diabetes; fibromyalgia; chronic rheumatic diseases; stroke; cerebral ischemia; respiratory failure; chronic respiratory disease; allergic diseases; overweight/obesity; drug use, wherein said subjects are not suffering from Long-Covid/fatigue post Covid-19 syndrome.
Absstract of: AU2023372393A1
Monoclonal antibodies that specifically bind to and block the function of Fas ligand (FasL) are described. The FasL-specific antibodies can be used for the development of therapeutics for the treatment of diseases, disorders and conditions associated with the Fas/FasL signaling pathway, such as cancer, sepsis, ischemia-reperfusion injury, and coronavirus disease 2019 (COVID-19).
Absstract of: US2025138005A1
Diagnostic assay devices for detecting the presence of an analyte in a sample solution may comprise a microreactor configured to form a sample solution containing the analyte, flow the sample solution therethrough in a first direction to form an analyte-capture molecule complex, and transfer the sample solution to an absorbent strip pad configured to flow therethrough, in a second direction crossing the first direction, the sample solution including the analyte-capture molecule complex and indicate a presence of the analyte-capture molecule complex. The diagnostic devices may be used, for example, to identify the presence of SARS-Cov2, RSV, influenza A, influenza B or other pathogens in samples from patients.
Absstract of: US2025138011A1
Kits containing a multiplexed chemiluminescent detection system and microfluidics devices and methods for detecting the presence and/or concentration of anti-SARS-CoV-2 antibodies in a sample are disclosed. The kits, microfluidics devices, and methods utilize singlet oxygen-activatable chemiluminescent compounds in combination with two or more fluorescent molecules that emit light at different wavelengths. In certain non-limiting embodiments, the kits, microfluidics devices, and methods can distinguish between anti-SARS-CoV-2 antibodies generated in response to vaccination from anti-SARS-CoV-2 antibodies generated in response to infection.
Absstract of: US2025138004A1
An apparatus for detecting a biomarker comprises a droplet harvesting structure for converting breath vapor to a fluid droplet for forming a fluid sample and a testing system having a biomarker testing zone for receiving the fluid sample and detecting a biomarker. The droplet harvesting structure may include at least one of a hydrophobic field for receiving the breath vapor and forming the fluid droplet from the received breath vapor and hydrophilic channels for receiving the fluid droplet and channeling the fluid droplet towards the testing system. A fluid dam member may be provided disposed between the droplet harvesting structure and the biomarker testing zone.
Absstract of: AU2023286504A1
The present disclosure provides methods for treating Post-Acute Sequelae of Severe Acute Respiratory Syndrome (SARS)-CoV-2 infection (PASC) or one or more symptoms associated with said PASC, comprising administering to a subject in need or at risk thereof a pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
Absstract of: EP4545970A2
The present invention relates to a peptide that specifically recognizes a protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a portion thereof; a composition for preventing or treating SARS-CoV-2 infection, comprising the peptide; and a composition for detecting SARS-CoV-2, comprising the peptide.
Absstract of: EP4545969A2
The present invention relates to a peptide that specifically recognizes a protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a portion thereof; a composition for preventing or treating SARS-CoV-2 infection, comprising the peptide; and a composition for detecting SARS-CoV-2, comprising the peptide.
Absstract of: KR20250058640A
본 발명은 세포 표면 가수분해효소를 이용하여 SARS-CoV-2 스파이크 단백질의 에피토프를 유산균의 세포 표면에 고정시키는 방법에 관한 것으로, 본 발명의 락티플랜티바실러스 플란타룸 균주 유래의 세포 표면 가수분해효소는 앵커 모티프를 가지고 있지 않음에도 불구하고, 사람에게 유익하고 안전성이 입증된 유산균의 세포 표면에 목적단백질을 고정시키는 효과가 우수하다. 따라서, 본 발명의 방법을 이용하면 백신용 항원을 간단하고 안전하게 생산할 수 있으므로, 생물공학, 치료용 단백질 의약품, 백신 등 다양한 분야에서 활용될 수 있을 것이다.
Absstract of: MA61946B1
The disclosure relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the disclosure relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.
Absstract of: MA61946B1
The disclosure relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the disclosure relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.
Absstract of: ZA202311432B
The present invention relates to a mutated SARS-CoV-2 spike protein, a variant or fragment thereof or an mRNA or DNA encoding them for use in the prevention of COVID-19.
Absstract of: EP4545559A2
The present invention is part of the field of genetic engineering, more specifically, in the field of production of anti-sars-cov-2 human monoclonal antibodies. The neutralizing human antibodies of the present application can be used in the therapy of COVID19, avoiding hospitalization and aggravation of infected people with a predisposition to develop severe disease. Persons who are not infected but at risk (health and safety professionals, and others) may benefit from preventive treatment. The present invention also relates to a pharmaceutical composition comprising anti-SARS-COV-2 human monoclonal antibodies, as well as a diagnostic kit and use thereof.
Absstract of: EP4545971A2
The present invention relates to a peptide that specifically recognizes a protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a portion thereof; a composition for preventing or treating SARS-CoV-2 infection, comprising the peptide; and a composition for detecting SARS-CoV-2, comprising the peptide.
Nº publicación: PL4230650T3 28/04/2025
Applicant:
RQBIO COVID LTD [GB]
RQBio Covid Limited
Absstract of: US2024376178A1
The invention relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.
BOPI
Electronic site
